A Congressional committee plans to subpoena AbbVie (ABBV) for documents about pricing practices for two of its best-selling medicines, after the drug maker failed to provide information lawmakers requested when an investigation was launched in January 2019.

At the time, the House Committee on Oversight and Reform sought data from a dozen large pharmaceutical companies about their pricing tactics for some of the most expensive medicines in response to nationwide angst over the rising cost of prescription drugs. AbbVie was asked for information about Humira, its rheumatoid arthritis treatment, and Imbruvica, a  medication for lymphoma.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy